Osteosarcoma

This study involves an investigational cellular therapy called Afamitresgene Autoleucel.

This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose.

The Mitochondria and Cancer Connections (MC²) Research program leverages knowledge from existing centers to establish a novel, cutting-edge research initiative and enable the development of mechanistic understanding and novel therapeutic opportunities at the intersection of mitochondrial disease and pediatric cancer.

The purpose of this study is to find the best dose of a drug called cabozantinib ("the study drug") to give to patients in combination with a routine chemotherapy drug called ifosfamide.